论文部分内容阅读
目的观察脑胶质瘤替尼泊甙动脉（VM_(26)）及口服司莫司汀（MeCCNU）化疗的疗效。方法对68例肿瘤切除手术后的脑胶质瘤病人行VM_(26)动脉超选择灌注及MeCCNU口服化疗，每间隔6－8周为一疗程，首次化疗后6个月将计算机体层摄影（CT）或磁共振成像（MRI）显示的肿瘤体积变化及临床症状评价与化疗前相比较。结果本组68例病人治疗后完全缓解9例（13．2％），部分缓解27例（39．8％），稳定19例（27．9％），恶化11例（16．2％，早期死亡（2．9％）。本组病例1年存活率89．7％，2年72．1％，3年以上存活率22．1％。全部病人无严重并发症及毒性反应。结论对手术切除的胶质瘤病人采用MeCCNU联合化疗，有益于提高胶质瘤病人的生存质量。
Objective To observe the therapeutic effect of teniposide artery (VM_ (26)) and oral administration of mothustine (MeCCNU) in glioma. Methods Sixty-eight patients with glioma after tumor resection were treated with VM 26 superselective perfusion and MeCCNU oral chemotherapy. Each treatment interval was 6-8 weeks. Six months after the first chemotherapy, CT) or magnetic resonance imaging (MRI) showed tumor volume changes and clinical symptoms compared with pre-chemotherapy. Results In the 68 patients, complete remission was achieved in 9 cases (13.2%), partial remission in 27 cases (39.8%), stabilization in 19 cases (27.9%) and deterioration in 11 cases (16.2% (2.9%). The 1-year survival rate was 89.7% in 2 years, 72.1% in 2 years and 22.1% in 3 years. All patients had no serious complications and toxicity. Resected glioma patients with MeCCNU combined chemotherapy, beneficial to improve the quality of life of patients with glioma.